

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2014											
(Rs in Lakh, except share data, per share data and unless otherwise stated)											
Sr. No.	Particulars	Standalone Financials					Consolidated Financials				
		3 Month Ended			15 Month Ended	Year Ended	3 Month Ended			15 Month Ended	Year Ended
		30.06.2014	31.03.2014	30.06.2013	31.03.2014	31.12.2012	30.06.2014	31.03.2014	30.06.2013	31.03.2014	31.12.2012
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
1	Income from Operations										
	a) Net Sales/Income from Operations	5,050.01	6,527.38	13,043.23	53,129.64	47,505.97	27,565.51	31,301.64	46,465.64	205,979.91	163,154.12
	b) Other Operating Income	222.21	(325.54)	1,506.87	3,652.46	2,138.36	222.21	(279.18)	1,526.86	3,863.40	2,215.26
	Total Income from operations (1+2)	5,272.22	6,201.83	14,550.10	56,782.10	49,644.34	27,787.72	31,022.46	47,992.50	209,843.31	165,369.38
2	Expenses										
	a) Cost of Material Consumed	2,729.40	2,421.59	5,066.43	19,378.53	25,155.50	6,776.58	6,708.36	14,590.56	37,638.91	37,998.20
	b) Purchase of Finished goods	890.84	1,405.98	5,614.63	21,919.89	15,311.45	8,080.51	8,445.47	10,282.12	87,290.26	58,941.28
	c) (Increase) / Decrease in Stock in trade & work in progress	52.71	98.32	(122.05)	543.94	(93.14)	320.48	1,294.54	(2,917.97)	(862.21)	(1,251.16)
	d) Employees Cost	558.56	580.37	681.49	3,370.37	2,891.51	3,082.85	3,043.89	2,182.67	15,959.71	11,891.54
	e) Depreciation/Amortization	204.00	208.79	247.82	1,039.79	880.24	1,523.55	1,578.57	1,005.31	6,422.85	1,772.98
	f) Other Expenditure	749.40	1,167.67	1,397.70	5,160.65	4,980.88	4,462.61	6,681.35	15,929.93	37,776.68	39,777.03
	Total Expenses	5,184.90	5,882.71	12,886.03	51,413.17	49,126.43	24,246.59	27,752.19	41,072.62	184,226.19	149,129.88
3	Profit / (Loss) from operation before other income, finance costs and exceptional items (1-2)	87.32	319.12	1,664.08	5,368.92	517.90	3,541.13	3,270.27	6,919.88	25,617.12	16,239.50
4	Other income	(37.20)	46.36	3.60	78.31	20.06	(40.37)	-	121.63	-	20.06
5	Profit (+) / Loss (-) from Ordinary Activities before finance costs and exceptional items (3+4)	50.13	365.48	1,667.68	5,447.23	537.96	3,500.76	3,270.27	7,041.51	25,617.12	16,259.56
6	Finance Costs	1,128.20	1,211.74	1,389.31	6,276.66	4,992.62	3,625.44	5,701.64	3,526.80	15,932.25	6,143.22
7	Profit / Loss from Ordinary Activities after finance costs but before exceptional items (5+6)	(1,078.07)	(846.26)	278.37	(829.43)	(4,454.66)	(124.68)	(2,431.37)	3,514.71	9,684.87	10,116.34
8	Exceptional items	-	-	(249.42)	-	3,749.48	-	-	(249.42)	-	811.48
9	Profit / Loss from Ordinary Activities before tax (7-8)	(1,078.07)	(846.26)	527.79	(829.43)	(705.18)	(124.68)	(2,431.37)	3,764.13	9,684.87	10,927.82
10	Tax expense	-	1.11	252.71	43.76	84.05	42.95	(1,232.93)	(676.29)	(1,383.82)	779.03
11	Net Profit / Loss from Ordinary Activities after tax (9-10)	(1,078.07)	(847.37)	275.07	(873.18)	(789.23)	(167.63)	(1,198.45)	4,440.42	11,068.69	10,148.80
12	Extra-Ordinary Items (net of tax expense)	-	-	-	-	-	-	-	-	-	-
13	Net Profit / Loss for the period (11+12)	(1,078.07)	(847.37)	275.07	(873.18)	(789.23)	(167.63)	(1,198.45)	4,440.42	11,068.69	10,148.80
14	Share of profit / (Loss) of associates	-	-	-	-	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-	-	-	-	-
16	Net Profit / Loss after taxes, minority interest and share of profit / (Loss) of associates (13+14+15)	(1,078.07)	(847.37)	275.07	(873.18)	(789.23)	(167.63)	(1,198.45)	4,440.42	11,068.69	10,148.80
17	Paid-up equity share capital (Nominal Value – Rs. 10/- each)	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67
18	Reserves excluding Revaluation reserves as per balance sheet of previous accounting year	-	-	-	50,456.02	51,329.21	-	-	-	157,975.87	133,290.26
19 i	Earning/(loss) per share (before Extra-Ordinary items) (not to be annualized) (Rs.)	-	-	-	-	-	-	-	-	-	-
	Basic	(3.16)	(2.49)	0.81	(2.56)	(2.32)	(0.49)	(3.52)	13.03	32.49	29.79
	Diluted	(3.16)	(2.49)	0.81	(2.56)	(2.32)	(0.49)	(3.52)	13.03	32.49	29.79
19 ii	Earning/(loss) per share (After-Ordinary items) (not to be annualized) (Rs.)	-	-	-	-	-	-	-	-	-	-
	Basic	(3.16)	(2.49)	0.81	(2.56)	(2.32)	(0.49)	(3.52)	13.03	32.49	29.79
	Diluted	(3.16)	(2.49)	0.81	(2.56)	(2.32)	(0.49)	(3.52)	13.03	32.49	29.79
A	PARTICULARS OF SHAREHOLDING										
1	Public Shareholding										
	a) Number of equity shares	9335737	8965737	7595622	8965737	5892622	9335737	8965737	7595622	8965737	5892622
	b) Percentage of Shareholding	27.40%	26.32%	22.30%	26.32%	17.30%	27.40%	26.32%	22.30%	26.32%	17.30%
2	Promoter and Promoter Group Shareholding :										
	a) Pledged/Encumbered										
	- Number of shares	21251885	21621885	22992000	21621885	27564950	21251885	21621885	22992000	21621885	27564950
	-Percentage of Shares (as a % of total shareholding of promoter and promoter group)	62.38%	63.47%	67.49%	63.47%	80.91%	62.38%	63.47%	67.49%	63.47%	80.91%
	- Percentage of shares (as a % of the total share capital of the Company)	85.93%	86.14%	86.86%	86.14%	97.84%	85.93%	86.14%	86.86%	86.14%	97.84%
	b) Non-encumbered										
	- Number of shares	3479045	3479045	3479045	3479045	609095	3479045	3479045	3479045	3479045	609095
	-Percentage of Shares (as a % of total shareholding of promoter and promoter group)	10.21%	10.21%	10.21%	10.21%	1.79%	10.21%	10.21%	10.21%	10.21%	1.79%
	- Percentage of shares (as a % of the total share capital of the Company)	14.07%	13.86%	13.14%	13.86%	2.16%	14.07%	13.86%	13.14%	13.86%	2.16%

B	INVESTOR COMPLAINTS	3 Month Ended
		30.06.2014
	Pending at the beginning of the quarter	0
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the quarter	0

Notes:-

- The above Unaudited Financial Results for the quarter ended 30th June, 2014 were approved at the meeting of the Board of Directors held on 13th August, 2014, after being approved and recommended by the Audit Committee.
- The Companies Act 2013 requires estimation of remaining useful life of all assets. Pending detailed assessment of the useful life and clarification from Ministry of Corporate Affairs, depreciation has been computed on the basis of the existing policy of the Company being followed upto 31st March, 2014. The difference between the current and revised computation, if any, will be recognised in subsequent quarters.
- The Company is engaged in a single segment viz. Pharmaceuticals which is governed by the same set of risks and returns, therefore the Accounting Standard (AS-17) on "Segment Reporting" issued by ICAI, is not applicable.
- The EPS has been computed in accordance with the accounting standards (AS-20) issued by the ICAI.
- Figures of the previous quarter / year wherever necessary have been regrouped and reclassified to confirm to those of the current quarter.
- The cost of Packing materials has been included in Material cost, whereas Directors' remuneration has been included in the employees cost.
- Reporting dates of the wholly owned subsidiaries Plethico International Ltd and Plethico Global Holdings B.V., Netherlands having different step-down subsidiaries particularly Plethico US Holding KFT Hungary, Natrol Inc., USA. and Natrol Global UAE, is as at 31st December and is different from the reporting date of the Parent Company, being March 31. The consolidated financial results comprises of its aforesaid subsidiaries and step-down subsidiaries. The financial results of the subsidiaries has been regrouped and / or reclassified wherever as per the requirements of Indian GAAP.
- The Company had issued Foreign Currency Convertible Bonds(FCCB) on 22nd October, 2007 which were due for repayment on 23rd October, 2012 or alternatively, the same was required to be converted into equity shares of the Company. Disputes had arisen between the Company, Trustee and bond holders and pursuant to which the Company had filed a suit for damages against Trustees for USD150million and a suit for damages against one of the purported Bond holder for USD250million at District Court, Indore Madhya Pradesh. In consequence thereof, the Trustees had filed a winding up petition against the Company which is pending for admission. The company has disputed the amount claimed by the Trustee on various grounds. The liability of the Company for payments towards principal and maturity premium of the FCCBs would depend upon the outcome of the aforesaid suit filed by the Company and also on the outcome of the winding up petition that has been filed against the company.
- The reference to the Corporate Debt Restructuring Cell (CDR Cell) on 29th March, 2014 for restructuring the debts of the Company has been admitted by the CDR cell on 28th June, 2014.
- The Company has not provided for contingent liabilities, including contingent tax liabilities in its books.

Date : 13.08.2014
Place : Mumbai



For PLETHICO PHARMACEUTICALS LIMITED
SHASHIKANT PATEL
CHAIRMAN CUM MANAGING DIRECTOR